Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2017

Open Access 01-12-2017 | Case report

The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report

Authors: Eun Hee Hong, Seong Joon Ahn, Han Woong Lim, Byung Ro Lee

Published in: BMC Ophthalmology | Issue 1/2017

Login to get access

Abstract

Background

Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss. We report a case of CME with HCQ retinopathy that improved with the use of oral acetazolamide, and discussed the possible mechanisms of CME in HCQ retinopathy using multimodal imaging modalities.

Case presentation

A 62-year-old patient with systemic lupus erythematosus (SLE) and HCQ retinopathy developed bilateral CME with visual decline. Fluorescein angiography (FA) showed fluorescein leakage in the macular and midperipheral area. After treatment with oral acetazolamide (250 mg/day) for one month, CME was completely resolved, best corrected visual acuity (BCVA) improved from 20/50 to 20/25, and FA examination showed decreased dye leakage in the macular and midperipheral areas.

Conclusions

In cases of vision loss in HCQ retinopathy, it is important to consider not only progression of maculopathy, but also development of CME, which can be effectively treated with oral acetazolamide.
Literature
1.
Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 2014;98:200–6.CrossRefPubMed
2.
Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141:850–8.CrossRefPubMed
3.
Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190–5.CrossRefPubMed
4.
Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107:1445–52.CrossRefPubMed
5.
Fishman GA, Gilbert LD, Anderson RJ, Marmor MF, Weleber RG, Viana MA. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994;101:687–93.CrossRefPubMed
6.
Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol. 1998;236:881–9.CrossRefPubMed
7.
Wolfensberger TJ. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97:387–97.CrossRefPubMed
8.
Marmor MF. Efficient and effective screening for hydroxychloroquine toxicity. Am J Ophthalmol. 2013;155:413–4.CrossRefPubMed
9.
Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond). 2011;25:1535–45.CrossRef
10.
Brown DM, s Benz M, Wong TP, Major JC. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clin Ophthalmol. 2010;4:1151–8.PubMedPubMedCentral
11.
Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology. 2015;122:110–6.CrossRefPubMed
12.
Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, Yoo B, Koo BS, Kim JT, Marmor MF, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015;122:1252–6.CrossRefPubMed
13.
Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol. 2011;21(Suppl 6):S10–9.CrossRefPubMed
14.
15.
Cunha-Vaz JG, Travassos A. Breakdown of the blood-retinal barriers and cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):485–92.CrossRefPubMed
16.
Fishman GA, Cunha-Vaz J, Salzano T. Vitreous fluorophotometry in patients with retinitis pigmentosa. Arch Ophthalmol. 1981;99:1202–7.CrossRefPubMed
17.
Kuchle M, Nguyen NX, Martus P, Freissler K, Schalnus R. Aqueous flare in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 1998;236:426–33.CrossRefPubMed
18.
Mallick KS, Zeimer RC, Fishman GA, Blair NP, Anderson RJ. Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa. Arch Ophthalmol. 1984;102:691–6.CrossRefPubMed
19.
Vinores SA, Kuchle M, Derevjanik NL, Henderer JD, Mahlow J, Green WR, Campochiaro PA. Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol. 1995;10:913–23.PubMed
20.
Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:e5–12.CrossRefPubMed
21.
Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:100–5.CrossRefPubMed
22.
Bhavsar KV, Mukkamala LK, Freund KB. Multimodal imaging in a severe case of hydroxychloroquine toxicity. Ophthalmic Surg Lasers Imaging Retina. 2015;46:377–9.CrossRefPubMed
23.
Parikh VS, Modi YS, Au A, Ehlers JP, Srivastava SK, Schachat AP, Singh RP. Nonleaking cystoid macular edema as a presentation of hydroxychloroquine retinal toxicity. Ophthalmology. 2016;123:664–6.CrossRefPubMed
24.
Takahashi J, Mori F, Hikichi T, Yoshida A. Effect of acetazolamide on outward permeability of blood-retina barrier using differential vitreous flyorophotometry. Curr Eye Res. 2001;23:166–70.CrossRefPubMed
25.
Moldow B, Sander B, Larsen M, Lund–Andersen H. Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest Ophthalmol Vis Sci. 1999;40:1770–5.PubMed
26.
Miller SS, Steinberg RH. Active transport of ions across frog retinal pigment epithelium. Exp Eye Res. 1977;25:235–48.CrossRefPubMed
27.
Marmor MF, Maack T. Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide. Invest Ophthalmol Vis Sci. 1982;23:121–4.PubMed
Metadata
Title
The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report
Authors
Eun Hee Hong
Seong Joon Ahn
Han Woong Lim
Byung Ro Lee
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2017
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-017-0517-0

Other articles of this Issue 1/2017

BMC Ophthalmology 1/2017 Go to the issue

Case report

Ocular manifestations as first signs of systemic T cell lymphoma in two cases

Case report

Combined Brown syndrome and superior oblique palsy without a trochlear nerve: case report

Research article

Prediction accuracy of intraocular lens power calculation methods after laser refractive surgery

Research article

A computerized red glass test for quantifying diplopia

Research article

Comparison of visual results and higher-order aberrations after small incision lenticule extraction (SMILE): high myopia vs. mild to moderate myopia

Case report

Correction of irregular and induced regular corneal astigmatism with toric IOL after posterior segment surgery: a case series